Versameb AG

Versameb AG is a biotechnology startup based in Switzerland, founded in 2017. Focused on pioneering the next generation of RNA therapeutics, the company specializes in discovering and developing innovative RNA-based drugs for modulation of protein expression. Versameb is known for its proprietary technology platform, VERSagile, which enables the application of functional RNA in different disease contexts, effectively making RNA druggable in new therapeutic areas traditionally considered challenging. Led by a seasoned scientific and leadership team, Versameb is committed to advancing its lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. The company's groundbreaking approach allows the simultaneous influence of several therapeutic targets in a controlled manner with one molecular construct, presenting a promising solution for complex medical conditions. In 2023, Versameb AG secured Fr.8.99M in Seed Round investment from Bernina BioInvest, marking a significant milestone in advancing its cutting-edge research and development. The company is actively working towards the completion of its first in-human/proof-of-concept clinical study, solidifying its position as a key player in the biotechnology and pharmaceutical industries. With its innovative approach and strong leadership, Versameb AG is poised to revolutionize the field of RNA therapeutics, offering potential breakthroughs in the treatment of various medical conditions.